Nuformix plc (LON:NFX – Get Free Report) hit a new 52-week low during mid-day trading on Friday. The company traded as low as GBX 0.10 and last traded at GBX 0.10, with a volume of 26,066,414 shares changing hands. The stock had previously closed at GBX 0.12.
Nuformix Stock Performance
The firm has a market cap of £2.69 million, a price-to-earnings ratio of -3.52 and a beta of 1.53. The business’s 50-day moving average is GBX 0.15 and its 200-day moving average is GBX 0.17.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Stories
- Five stocks we like better than Nuformix
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
